货号:A326754
同义名:
制霉菌素
/ Fungicidin
Nystatin是一种多烯类抗真菌剂,与真菌细胞膜上的甾醇结合,使细胞膜通透性改变。Nystatin能够抑制真菌的活性,可用于细胞培养,推荐浓度为 0.05mg/mL。


| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 描述 | Nystatin is an orally active polyene antifungal antibiotic effective against yeast and mycoplasma. Nystatin results in a significant reduction in buccal epithelial cell adhesion of all six Candida species[3]. Histopathological results showed that liposomal nystatin cleared the lungs, spleen, pancreas, kidney, and liver of Aspergillus and that there was no organ damage at the day 5 time point, which was after only three doses of liposomal nystatin. Based on these results in mice, it is probable that liposomal nystatin will be effective against Aspergillus infection in humans[4]. Nystatin-enhanced internalization of endostatin also increases its inhibitory effects on endothelial cell tube formation and migration. More importantly, combined treatment with nystatin and endostatin selectively enhances endostatin uptake and biodistribution in tumor blood vessels and tumor tissues but not in normal tissues of tumor-bearing mice, ultimately resulting in elevated antiangiogenic and antitumor efficacies of endostatin in vivo[5]. |
| 体外研究 | Nystatin causes a significant reduction in buccal epithelial cell adhesion in all six Candida species[6]. Nystatin is an antibiotic that increases the permeability of the plasma membrane to small monovalent ions, including chloride ions.Nystatin increases apical chloride permeability, such that trans-epithelial transport of chloride ions is limited by translocation across the basolateral membranes of tracheal epithelial cells, largely reflecting the activity of co-transporter proteins.Nystatin (400 units/mL) increases the basal level of trans-epithelial 36Cl flux by approximately 1.5-fold and eliminated the stimulation of this flux by UTP.Nystatin treatment also eliminated the stimulation of binding of saturable basolateral [3H]bumetanide by UTP, a measure of the function of Na-K-Cl co-transporter proteins in these cells; stimulation of binding by isoproterenol was only mildly inhibited by Nystatin treatment[7]. Nystatin significantly enhances endothelial uptake by endothelial cells by converting endothelial inhibitor internalisation primarily to a lattice protein-mediated pathway.Nystatin-enhanced endothelial inhibitor internalisation also increases its inhibitory effect on endothelial cell tube formation and migration[8]. |
| Concentration | Treated Time | Description | References | |
| C. lipolytica | 0.125–16 µg/ml | 24 and 48 hours | To evaluate the in vitro activity of nystatin and liposomal nystatin against C. lipolytica, results showed that nystatin and liposomal nystatin exhibited good activity against all tested Candida species. | J Clin Microbiol. 2002 Apr;40(4):1406-12. |
| C. lusitaniae | 0.125–16 µg/ml | 24 and 48 hours | To evaluate the in vitro activity of nystatin and liposomal nystatin against C. lusitaniae, results showed that nystatin and liposomal nystatin exhibited good activity against all tested Candida species. | J Clin Microbiol. 2002 Apr;40(4):1406-12. |
| C. krusei | 0.125–16 µg/ml | 24 and 48 hours | To evaluate the in vitro activity of nystatin and liposomal nystatin against C. krusei, results showed that nystatin and liposomal nystatin exhibited good activity against all tested Candida species. | J Clin Microbiol. 2002 Apr;40(4):1406-12. |
| C. parapsilosis | 0.125–16 µg/ml | 24 and 48 hours | To evaluate the in vitro activity of nystatin and liposomal nystatin against C. parapsilosis, results showed that nystatin and liposomal nystatin exhibited good activity against all tested Candida species. | J Clin Microbiol. 2002 Apr;40(4):1406-12. |
| C. tropicalis | 0.125–16 µg/ml | 24 and 48 hours | To evaluate the in vitro activity of nystatin and liposomal nystatin against C. tropicalis, results showed that nystatin and liposomal nystatin exhibited good activity against all tested Candida species. | J Clin Microbiol. 2002 Apr;40(4):1406-12. |
| C. glabrata | 0.125–16 µg/ml | 24 and 48 hours | To evaluate the in vitro activity of nystatin and liposomal nystatin against C. glabrata, results showed that nystatin and liposomal nystatin exhibited good activity against all tested Candida species. | J Clin Microbiol. 2002 Apr;40(4):1406-12. |
| C. albicans | 0.125–16 µg/ml | 24 and 48 hours | To evaluate the in vitro activity of nystatin and liposomal nystatin against C. albicans, results showed that nystatin and liposomal nystatin exhibited good activity against all tested Candida species. | J Clin Microbiol. 2002 Apr;40(4):1406-12. |
| HEK-293 cells | 3.9 to 125 µg/mL | 24 hours | To evaluate the cytotoxicity of Nystatin nanocomposites on HEK-293 cells. Results showed that nanocomposites inhibited only 12% growth of HEK-293 cells at 125 µg/mL, indicating low cytotoxicity. | Molecules. 2023 Feb 15;28(4):1836. |
| Candida dubliniensis CD36 | 3.52 mg/L (MIC) | 24 hours | Evaluation of the minimum inhibitory concentration (MIC) of Nystatin against Candida dubliniensis CD36, showing an MIC of 3.52 mg/L. | essential oil inhibits virulence patterns of Candida spp. and potentiates the effects of fluconazole and nystatin in vitro. |
| Candida krusei ATCC 6258 | 1.40 mg/L (MIC) | 24 hours | Evaluation of the minimum inhibitory concentration (MIC) of Nystatin against Candida krusei ATCC 6258, showing an MIC of 1.40 mg/L. | essential oil inhibits virulence patterns of Candida spp. and potentiates the effects of fluconazole and nystatin in vitro. |
| Candida albicans ATCC 10231 | 0.48 mg/L (MIC) | 24 hours | Evaluation of the minimum inhibitory concentration (MIC) of Nystatin against Candida albicans ATCC 10231, showing an MIC of 0.48 mg/L. | essential oil inhibits virulence patterns of Candida spp. and potentiates the effects of fluconazole and nystatin in vitro. |
| Candida albicans ATCC 90029 | 0.33 mg/L (MIC) | 24 hours | Evaluation of the minimum inhibitory concentration (MIC) of Nystatin against Candida albicans ATCC 90029, showing an MIC of 0.33 mg/L. | essential oil inhibits virulence patterns of Candida spp. and potentiates the effects of fluconazole and nystatin in vitro. |
| Pichia kudriavzevii | 8-64 µg/ml | 24-48 hours | To evaluate the Minimum Inhibitory Concentration (MIC) and Minimum Fungicidal Concentration (MFC) of Nystatin against P. kudriavzevii. Results showed that 61.9% of isolates had dose-dependent sensitivity to Nystatin, while 28.57% were resistant. | BMC Microbiol. 2024 Sep 10;24(1):333. |
| Candida albicans SC5314 | 0.25–1 µM | 3 days | Inhibition of filamentation in C. albicans, with enhanced efficacy when combined with 4-AQ derivatives | NPJ Biofilms Microbiomes. 2024 Dec 13;10(1):146. |
| Candida dubliniensis 40/01 | 0.0156–16 µg/ml | 48 hours | To evaluate the effect of OligoG in combination with nystatin on the minimum inhibitory concentration (MIC) of Candida dubliniensis. Results showed a 32-fold reduction in MIC value when nystatin was used in combination with 6% OligoG. | Front Cell Infect Microbiol. 2023 Jan 31;13:1122340. |
| Candida auris NCPF 8971 | 0.0156–16 µg/ml | 48 hours | To evaluate the effect of OligoG in combination with nystatin on the minimum inhibitory concentration (MIC) of Candida auris. Results showed a 2-fold reduction in MIC value when nystatin was used in combination with 6% OligoG. | Front Cell Infect Microbiol. 2023 Jan 31;13:1122340. |
| Candida parapsilosis W23 | 0.0156–16 µg/ml | 48 hours | To evaluate the effect of OligoG in combination with nystatin on the minimum inhibitory concentration (MIC) of Candida parapsilosis. Results showed a 4-fold reduction in MIC value when nystatin was used in combination with 6% OligoG. | Front Cell Infect Microbiol. 2023 Jan 31;13:1122340. |
| Candida albicans ATCC 90028 | 0.0156–16 µg/ml | 48 hours | To evaluate the effect of OligoG in combination with nystatin on the minimum inhibitory concentration (MIC) of Candida albicans. Results showed a 4-fold reduction in MIC value when nystatin was used in combination with 6% OligoG. | Front Cell Infect Microbiol. 2023 Jan 31;13:1122340. |
| Candida albicans | 3.9 to 500 µg/mL | 48 hours | To evaluate the inhibitory effect of Nystatin nanocomposites on the growth of Candida albicans. Results showed that nanocomposites significantly inhibited the growth of C. albicans at a concentration of 3.9 µg/mL. | Molecules. 2023 Feb 15;28(4):1836. |
| C. albicans ATCC 26278 | 100 μg/mL | Overnight | To determine the minimum inhibitory concentration of Nystatin-PLP adduct, showing attenuated antifungal potency. | Mol Pharm. 2011 Feb 7;8(1):297-301. |
| Administration | Dosage | Frequency | Description | References | ||
| Zebrafish (Danio rerio) | Disseminated candidiasis model | 0.5–1 µM | Assessed after 24-hour treatment | Increased survival rate of infected embryos, with enhanced efficacy when combined with 4-AQ derivatives | NPJ Biofilms Microbiomes. 2024 Dec 13;10(1):146. | |
| ICR female mice | Vulvovaginal candidiasis (VVC) model | Vaginal perfusion | 50.0 µL/dose | Administered on days 1, 6, and 16, with therapeutic effects monitored | Assess the therapeutic efficacy of ENNE against VVC, demonstrating significant reduction in vaginal fungal load and improved inflammatory response | Int J Nanomedicine. 2020 Mar 25;15:2027-2044 |
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT00659971 | Oral Candidiasis | Phase 2 | Completed | - | United States, North Carolina ... 展开 >> Rosedale Infectious Disease Huntersville, North Carolina, United States, 28078 收起 << |
| NCT01111942 | Head and Neck Cancer | Early Phase 1 | Terminated(lack of enrollment) | - | United States, Illinois ... 展开 >> Southern Illinois University School of Medicine Springfield, Illinois, United States, 62701 收起 << |
| NCT00814359 | Head and Neck Cancer ... 展开 >> Mucositis 收起 << | Phase 3 | Completed | - | Canada, Ontario ... 展开 >> Juravinski Cancer Centre Hamilton, Ontario, Canada, L8V 5C2 收起 << |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
1.08mL 0.22mL 0.11mL |
5.40mL 1.08mL 0.54mL |
10.80mL 2.16mL 1.08mL |
|
| CAS号 | 1400-61-9 |
| 分子式 | C47H75NO17 |
| 分子量 | 926.09 |
| SMILES Code | C[C@@H]1OC(C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@@](O)(O[C@H]2C[C@H](/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@@H]([C@@H](O)[C@H]1C)C)O[C@H]3[C@@H](O)[C@@H](N)[C@H](O)[C@@H](C)O3)C[C@H](O)[C@H]2C(O)=O)=O |
| MDL No. | MFCD00036240 |
| 别名 | 制霉菌素 ;Fungicidin |
| 运输 | 蓝冰 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Keep in dark place, inert atmosphere, store in freezer, under -20°C |
| 溶解方案 |
DMSO: 50 mg/mL(53.99 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1